MX359476B - Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3). - Google Patents

Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3).

Info

Publication number
MX359476B
MX359476B MX2014007919A MX2014007919A MX359476B MX 359476 B MX359476 B MX 359476B MX 2014007919 A MX2014007919 A MX 2014007919A MX 2014007919 A MX2014007919 A MX 2014007919A MX 359476 B MX359476 B MX 359476B
Authority
MX
Mexico
Prior art keywords
tumours
glycolyl
ganglioside
treatment
pharmaceutical compositions
Prior art date
Application number
MX2014007919A
Other languages
English (en)
Other versions
MX2014007919A (es
Inventor
Casimiro José Enrique Montero
Monzón Kalet León
Palomo Adys González
Perez Adriana Carr
Santana Rancés Blanco
Abraham Amparo Emilia Macías
Alvarez María Del Carmen Barroso
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47435671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359476(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of MX2014007919A publication Critical patent/MX2014007919A/es
Publication of MX359476B publication Critical patent/MX359476B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para el tratamiento de tumores malignos; particularmente aquellos tumores que expresan los blancos REGF y gangliósido N-glicolil GM3 con el fin de potenciar el efecto terapéutico que producen las terapias contra dichos blancos por separado; las composiciones farmacéuticas de la invención comprenden anticuerpos y/o vacunas contra cada uno de los blancos; adicionalmente la presente invención se refiere a los métodos para la aplicación de las composiciones de la invención.
MX2014007919A 2011-12-27 2012-12-04 Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3). MX359476B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20110245A CU24070B1 (es) 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
PCT/CU2012/000007 WO2013097834A1 (es) 2011-12-27 2012-12-04 COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES QUE EXPRESAN REGF Y GANGLIÓSIDO N-GLICOLIL GM3 (NeuGcGM3)

Publications (2)

Publication Number Publication Date
MX2014007919A MX2014007919A (es) 2014-07-30
MX359476B true MX359476B (es) 2018-09-27

Family

ID=47435671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007919A MX359476B (es) 2011-12-27 2012-12-04 Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3).

Country Status (26)

Country Link
US (1) US9790279B2 (es)
EP (1) EP2805747B1 (es)
JP (1) JP6027137B2 (es)
KR (1) KR101703637B1 (es)
CN (1) CN103998098B (es)
AR (1) AR089490A1 (es)
AU (1) AU2012361321C1 (es)
BR (1) BR112014015693B1 (es)
CA (1) CA2855182C (es)
CL (1) CL2014001236A1 (es)
CO (1) CO6990729A2 (es)
CU (1) CU24070B1 (es)
EA (1) EA030346B1 (es)
ES (1) ES2694324T3 (es)
IL (1) IL233323B (es)
MX (1) MX359476B (es)
MY (1) MY185138A (es)
PE (1) PE20142328A1 (es)
PH (1) PH12014501202A1 (es)
SG (1) SG11201403014XA (es)
TN (1) TN2014000203A1 (es)
TR (1) TR201816232T4 (es)
TW (1) TWI523663B (es)
UA (1) UA111403C2 (es)
WO (1) WO2013097834A1 (es)
ZA (1) ZA201405424B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188874T1 (de) * 1992-08-18 2000-02-15 Centro Inmunologia Molecular Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen
CN1103404A (zh) * 1993-03-01 1995-06-07 分子免疫中心 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Also Published As

Publication number Publication date
WO2013097834A1 (es) 2013-07-04
EA030346B1 (ru) 2018-07-31
CO6990729A2 (es) 2014-07-10
CU20110245A7 (es) 2013-08-29
US9790279B2 (en) 2017-10-17
TN2014000203A1 (en) 2015-09-30
UA111403C2 (uk) 2016-04-25
BR112014015693A2 (pt) 2017-06-13
CA2855182C (en) 2018-06-12
CN103998098A (zh) 2014-08-20
BR112014015693B1 (pt) 2023-03-21
BR112014015693A8 (pt) 2017-07-04
PE20142328A1 (es) 2015-01-29
PH12014501202A1 (en) 2014-09-08
TWI523663B (zh) 2016-03-01
AU2012361321A1 (en) 2014-07-24
CL2014001236A1 (es) 2014-08-08
TW201336509A (zh) 2013-09-16
ZA201405424B (en) 2016-02-24
MX2014007919A (es) 2014-07-30
AU2012361321C1 (en) 2016-03-10
US20140363494A1 (en) 2014-12-11
SG11201403014XA (en) 2014-09-26
NZ627012A (en) 2016-01-29
EP2805747A1 (en) 2014-11-26
JP6027137B2 (ja) 2016-11-16
IL233323A0 (en) 2014-08-31
MY185138A (en) 2021-04-30
JP2015506354A (ja) 2015-03-02
AU2012361321A8 (en) 2014-08-07
EA201491284A1 (ru) 2014-09-30
ES2694324T3 (es) 2018-12-19
CA2855182A1 (en) 2013-07-04
KR20140100538A (ko) 2014-08-14
EP2805747B1 (en) 2018-10-17
CN103998098B (zh) 2017-08-04
KR101703637B1 (ko) 2017-02-07
AU2012361321B2 (en) 2015-11-19
IL233323B (en) 2018-11-29
CU24070B1 (es) 2015-01-29
AR089490A1 (es) 2014-08-27
TR201816232T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EA201400625A1 (ru) Антитела против pd-l1 и их применение
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
IN2014KN00848A (es)
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
MX349004B (es) Nuevos compuestos.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX381456B (es) Regulador de ph de transduccion.
PH12014502406B1 (en) Anti-il-23p19 antibodies
GB201209613D0 (en) New compounds
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
GB201118656D0 (en) New compounds
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PH12015501360A1 (en) Bmp-6 antibodies
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
IN2014DN03010A (es)
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX359476B (es) Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3).
HK1258843A1 (zh) 糖脂化合物及其在治疗肿瘤中的用途
BR112013033807A2 (pt) formulações pirroloquinolinil-pirrolidin-2,5-diona e métodos para sua preparação
TH1401003675A (th) องค์ประกอบทางเภสัชกรรมสำหรับการรักษาเนื้องอกที่แสดง EGFR และ แกงกลิโอไซด์ N-ไกลโคลิล GM3 (NeuGcGM3)
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration